New synthetic anticoagulants made from carbohydrate polymers
Sulfated Poly-Amido-Saccharide (sulPAS) Biomaterials as Anticoagulants
This study is testing a new type of blood thinner called sulPAS that could work better and have fewer side effects than traditional options like heparin, helping people with blood clotting issues manage their condition more safely.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10873098 on NIH RePORTER |
What this research studies
This research investigates a novel biomaterial called sulfated poly-amido-saccharides (sulPAS) that can serve as synthetic anticoagulants. The study aims to address the limitations of traditional anticoagulants like heparin, which can have variable effects and serious side effects. By creating a more consistent and effective alternative, the research will explore the synthesis, mechanisms of action, and efficacy of these new anticoagulants through various laboratory studies. Patients may benefit from improved management of blood clotting disorders with fewer risks associated with current treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with blood coagulation disorders who require anticoagulant therapy.
Not a fit: Patients who do not have blood coagulation disorders or those who are not candidates for anticoagulant therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective anticoagulant therapies for patients with blood clotting disorders.
How similar studies have performed: Other research has shown promise in developing synthetic anticoagulants, but this approach using sulPAS is relatively novel.
Where this research is happening
Boston, United States
- Boston University (Charles River Campus) — Boston, United States (Active)
Researchers
- Principal investigator: Grinstaff, Mark W. — Boston University (Charles River Campus)
- Study coordinator: Grinstaff, Mark W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.